Gout Therapeutic Market Size, Share, Growth, Trends, and Forecast 2020-2027

1.Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Gout Therapeutics Market

4. Market Overview
4.1. Introduction
4.1.1. Component Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Epidemiological Overview of Gout Arthritis
5.2.Pipeline Analysis

6. Global Gout Therapeutics Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2026
6.3.1. Colchicine
6.3.2. Antihyperuricemic agents (Urate-Lowering Drugs)
6.3.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
6.3.4. Corticosteroids
6.3.5. Biologic Response Modifiers (Biologics)
6.4. Global Gout Therapeutics Market Attractiveness, by Drug Type

7 Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2026
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Global Gout Therapeutics Market Attractiveness, by Distribution Channel

8. Global Gout Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Gout Therapeutics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Gout Therapeutics Market Attractiveness, by Country/Region

9. North America Gout Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2026
9.2.1. Colchicine
9.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
9.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
9.2.4. Corticosteroids
9.2.5. Biologic Response Modifiers (Biologics)
9.3. North America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2026
9.3.1. Hospital Pharmacy
9.3.2. Retail Pharmacy
9.3.3. Online Pharmacy
9.4. North America Gout Therapeutics Market Value Forecast, by Country, 2017–2026
9.4.1. U.S.
9.4.2. Canada
9.5. North America Gout Therapeutics Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Gout Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2026
10.2.1. Colchicine
10.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
10.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
10.2.4. Corticosteroids
10.2.5. Biologic Response Modifiers (Biologics)
10.3. Europe Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2026
10.3.1. Hospital Pharmacy
10.3.2. Retail Pharmacy
10.3.3. Online Pharmacy
10.4. Europe Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Gout Therapeutics Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Asia Pacific Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2026
11.2.1. Colchicine
11.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
11.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
11.2.4. Corticosteroids
11.2.5. Biologic Response Modifiers (Biologics)
11.3. Asia Pacific Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2026
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Online Pharmacy
11.4. Asia Pacific Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2026
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Gout Therapeutics Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Gout Therapeutics Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Latin America Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2026
12.2.1. Colchicine
12.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
12.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
12.2.4. Corticosteroids
12.2.5. Biologic Response Modifiers (Biologics)
12.3. Latin America Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2026
12.3.1. Hospital Pharmacy
12.3.2. Retail Pharmacy
12.3.3. Online Pharmacy
12.4. Latin America Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Gout Therapeutics Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Gout Therapeutics Market Value Forecast, by Drug Type, 2017–2026
13.2.1. Colchicine
13.2.2. Antihyperuricemic agents (Urate-Lowering Drugs)
13.2.3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
13.2.4. Corticosteroids
13.2.5. Biologic Response Modifiers (Biologics)
13.3. Middle East & Africa Gout Therapeutics Market Value Forecast, by Distribution Channel, 2017–2026
13.3.1. Hospital Pharmacy
13.3.2. Retail Pharmacy
13.3.3. Online Pharmacy
13.4. Middle East & Africa Gout Therapeutics Market Value Forecast, by Country/Sub-region, 2017–2026
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5.Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Company Profiles
14.1.1. Takeda Pharmaceutical Company Limited
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.1.2 Product Portfolio
14.1.1.3. SWOT Analysis
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Teijin Pharma Limited
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.2.2 Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.3. Novartis AG
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.3.2 Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Mylan N.V.
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.4.2 Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Horizon Pharma plc.
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.5.2 Product Portfolio
14.1.5.3. SWOT Analysis
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Teva Pharmaceutical Industries Ltd.
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.6.2 Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview
14.1.7 Hikma Pharmaceuticals PLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.7.5. Financial Overview
14.1.8. Iroko Pharmaceuticals, LLC
14.1.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.7.2 Product Portfolio
14.1.7.3. SWOT Analysis
14.1.7.4. Strategic Overview
14.1.9. MERCK & CO., Inc.
14.1.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.1.9.2 Product Portfolio
14.1.9.3. SWOT Analysis
14.1.9.4. Strategic Overview
14.1.9.5. Financial Overview